Abbott Laboratories (NYSE:ABT – Free Report) had its price target reduced by The Goldman Sachs Group from $140.00 to $121.00 in a research report released on Wednesday,MarketScreener reports. The Goldman Sachs Group currently has a buy rating on the healthcare product maker’s stock.
Other equities analysts also recently issued reports about the stock. Weiss Ratings downgraded shares of Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, January 26th. BTIG Research lowered their target price on shares of Abbott Laboratories from $140.00 to $131.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. Piper Sandler lowered their target price on shares of Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating on the stock in a report on Friday, January 23rd. Sanford C. Bernstein reduced their price objective on shares of Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Finally, Raymond James Financial reduced their price objective on shares of Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $134.58.
View Our Latest Stock Report on ABT
Abbott Laboratories Price Performance
Abbott Laboratories (NYSE:ABT – Get Free Report) last released its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, meeting the consensus estimate of $1.50. The business had revenue of $11.46 billion during the quarter, compared to analysts’ expectations of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The firm’s revenue was up 4.4% on a year-over-year basis. During the same period last year, the business earned $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Equities research analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.
Abbott Laboratories Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date of this dividend is Wednesday, April 15th. Abbott Laboratories’s payout ratio is presently 67.74%.
Insider Buying and Selling
In other news, VP John A. Jr. Mccoy sold 585 shares of the business’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $67,614.30. Following the completion of the sale, the vice president owned 24,628 shares of the company’s stock, valued at approximately $2,846,504.24. The trade was a 2.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Daniel Gesua Sive Salvadori sold 885 shares of the business’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $102,288.30. Following the completion of the sale, the executive vice president directly owned 146,377 shares of the company’s stock, valued at approximately $16,918,253.66. The trade was a 0.60% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 3,055 shares of company stock valued at $353,097 in the last 90 days. 0.46% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Abbott Laboratories
Several institutional investors and hedge funds have recently bought and sold shares of the company. J. Derek Lewis & Associates Inc. bought a new stake in Abbott Laboratories during the fourth quarter worth about $1,992,000. Purpose Unlimited Inc. bought a new stake in Abbott Laboratories during the fourth quarter worth about $25,000. Stance Capital LLC lifted its position in Abbott Laboratories by 12.8% during the fourth quarter. Stance Capital LLC now owns 11,339 shares of the healthcare product maker’s stock worth $1,421,000 after purchasing an additional 1,291 shares during the period. Cornerstone Planning LLC bought a new stake in Abbott Laboratories during the fourth quarter worth about $2,858,000. Finally, Rockefeller Capital Management L.P. lifted its position in Abbott Laboratories by 27.5% during the fourth quarter. Rockefeller Capital Management L.P. now owns 1,377,659 shares of the healthcare product maker’s stock worth $172,607,000 after purchasing an additional 297,268 shares during the period. Institutional investors own 75.18% of the company’s stock.
Abbott Laboratories News Summary
Here are the key news stories impacting Abbott Laboratories this week:
- Positive Sentiment: Barclays raised its price target on ABT to $144 and keeps an “overweight” view, a bullish signal that likely helped buying interest. Abbott Laboratories price target raised by Barclays
- Positive Sentiment: Coverage highlighting Abbott as a “dividend king on sale” (value/dividend investors) increases interest from income-focused buyers given its long track record of payout consistency. A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?
- Neutral Sentiment: Several sell‑side analysts remain constructive (maintaining buy/outperform ratings) but trimmed targets modestly (Evercore to $134 from $138; BTIG similar), which is mixed news — keeps analyst support but reduces implied upside. Evercore ISI and BTIG Lower Abbott (ABT) Price Targets, Maintain Positive Ratings
- Neutral Sentiment: Analysts and media note the stock’s recent underperformance versus the broader market even as it edges up intraday — an important context for short‑term momentum traders. Abbott Laboratories stock rises Wednesday, still underperforms market
- Negative Sentiment: Goldman Sachs cut its price target sharply to $121 from $140 (still a “buy”), a downgrade in expectation that can pressure sentiment and cap near‑term gains. Goldman Sachs adjusts price target on Abbott Laboratories to $121 from $140; maintains buy rating
- Negative Sentiment: Analyses flag recent share weakness (down materially over the past 1–3 months) and fading momentum; fundamental concerns include a modest revenue shortfall in the last quarter despite EPS in line and only modest FY guidance — reasons some investors remain cautious. Assessing Abbott Laboratories (ABT) Valuation After Recent Share Price Weakness
Abbott Laboratories Company Profile
Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.
In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.
Further Reading
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
